Metabolic evidence of viable myocardium in regions with reduced wall thickness and absent wall thickening in patients with chronic ischemic left ventricular dysfunction

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.

Reduced end-diastolic wall thickness with absent systolic wall thickening has been reported to represent nonviable myocardium in patients with chronic coronary artery disease. To assess whether reduced regional end-diastolic wall thickness and absent wall thickening accurately identify nonviable myocardium, 25 patients with ischemic left ventricular dysfunction (ejection fraction at rest 27 +/- 10%) underwent positron emission tomography with oxygen-15-labeled water and 18fluorodeoxyglucose to assess metabolic activity and spin-echo gated nuclear magnetic resonance imaging to measure regional end-diastolic wall thickness and wall thickening. The presence of metabolic activity was defined as 18fluorodeoxyglucose uptake (corrected for partial volume) greater than 50% of that in normal regions. Of 355 myocardial regions evaluated, 266 were hypokinetic or normokinetic at rest and 89 were akinetic (that is, absent wall thickening). 18Fluorodeoxyglucose uptake was observed in 97% of the hypokinetic and normokinetic regions and in 74% of the akinetic regions. End-diastolic wall thickness was greater in akinetic regions with than in those without 18fluorodeoxyglucose uptake (11 +/- 4 vs. 7 +/- 3 mm, p less than 0.01). The highest values for sensitivity and specificity of end-diastolic wall thickness in predicting the absence of metabolic activity in akinetic regions were 74% and 79%, respectively, and corresponded to an end-diastolic threshold of 8 mm. However, the positive predictive accuracy was only 55% and did not improve for other end-diastolic wall thickness values. In all myocardial regions, there was only a weak correlation between 18fluorodeoxyglucose activity and either end-diastolic wall thickness (r = 0.17) or wall thickening (r = 0.32). Thus, metabolic activity is present in many regions with reduced end-diastolic wall thickness and absent wall thickening. These data indicate that assessment of regional anatomy and function may be inaccurate in distinguishing asynergic but viable myocardium from nonviable myocardium.

This article has been cited by other articles:

				Y. Zhang, A. K.Y. Chan, C.-M. Yu, G. W.K. Yip, J. W.H. Fung, W. W.M. Lam, N. M.C. So, M. Wang, E. B. Wu, J. T. Wong, et al. Strain Rate Imaging Differentiates Transmural From Non-Transmural Myocardial Infarction: A Validation Study Using Delayed-Enhancement Magnetic Resonance Imaging J. Am. Coll. Cardiol., September 6, 2005; 46(5): 864 - 871. [Abstract] [Full Text] [PDF]

				A. N. Mazzadi, M. F. Janier, B. Brossier, X. Andre-Fouet, E. McFadden, D. Revel, and P. Croisille Dobutamine-tagged MRI for inotropic reserve assessment in severe CAD: relationship with PET findings Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1946 - H1953. [Abstract] [Full Text] [PDF]

				H. Mahrholdt, A. Wagner, R.M. Judd, and U. Sechtem Assessment of myocardial viability by cardiovascular magnetic resonance imaging Eur. Heart J., April 2, 2002; 23(8): 602 - 619. [Full Text] [PDF]

				G LaCanna, S.H Rahimtoola, O Visioli, R Giubbini, O Alfieri, M Zognio, E Milan, C Ceconi, M Gargano, R LoRusso, et al. Sensitivity, specificity, and predictive accuracies of non-invasive tests, singly and in combination, for diagnosis of hibernating myocardium Eur. Heart J., August 2, 2000; 21(16): 1358 - 1367. [Abstract] [PDF]

				M. Salati, M. Lemma, D. G. Di Mattia, P. Danna, A. Cialfi, A. Salvaggio, and C. Santoli Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: Functional Observations Ann. Thorac. Surg., December 1, 1997; 64(6): 1728 - 1734. [Abstract] [Full Text]

				P. Perrone-Filardi, L. Pace, M. Prastaro, F. Squame, S. Betocchi, A. Soricelli, F. Piscione, C. Indolfi, T. Crisci, M. Salvatore, et al. Assessment of Myocardial Viability in Patients With Chronic Coronary Artery Disease: Rest–4-Hour–24-Hour 201Tl Tomography Versus Dobutamine Echocardiography Circulation, December 1, 1996; 94(11): 2712 - 2719. [Abstract] [Full Text]

				C. R. deFilippi, D. L. Willett, W. N. Irani, E. J. Eichhorn, C. E. Velasco, and P. A. Grayburn Comparison of Myocardial Contrast Echocardiography and Low-Dose Dobutamine Stress Echocardiography in Predicting Recovery of Left Ventricular Function After Coronary Revascularization in Chronic Ischemic Heart Disease Circulation, November 15, 1995; 92(10): 2863 - 2868. [Abstract] [Full Text]

				E. E. van der Wall, H. W. Vliegen, A. de Roos, and A. V.G. Bruschke Magnetic Resonance Imaging in Coronary Artery Disease Circulation, November 1, 1995; 92(9): 2723 - 2739. [Abstract] [Full Text]

				P. Perrone-Filardi, L. Pace, M. Prastaro, F. Piscione, S. Betocchi, F. Squame, P. Vezzuto, A. Soricelli, C. Indolfi, M. Salvatore, et al. Dobutamine Echocardiography Predicts Improvement of Hypoperfused Dysfunctional Myocardium After Revascularization in Patients With Coronary Artery Disease Circulation, May 15, 1995; 91(10): 2556 - 2565. [Abstract] [Full Text]

				F. M. Baer, E. Voth, C. A. Schneider, P. Theissen, H. Schicha, and U. Sechtem Comparison of Low-Dose Dobutamine–Gradient-Echo Magnetic Resonance Imaging and Positron Emission Tomography With [18F]Fluorodeoxyglucose in Patients With Chronic Coronary Artery Disease : A Functional and Morphological Approach to the Detection of Residual Myocardial Viability Circulation, February 15, 1995; 91(4): 1006 - 1015. [Abstract] [Full Text]